Injectable gel for long-lasting pain relief after surgery
Extended-release injectable gel for multi-day treatment of postoperative pain
This study is testing a new injectable gel that helps relieve pain after surgery without using opioids, making recovery safer and more comfortable for patients dealing with moderate-to-severe pain.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sonoran Biosciences, INC. NIH-funded |
| Lab location | 1 site (Tempe, United States) |
| Project ID | NIH-11066703 on NIH RePORTER |
What this research studies
This research focuses on developing an injectable gel that can provide effective pain relief for patients recovering from surgery without the need for opioids. The gel, which contains bupivacaine, is designed to release medication over an extended period, specifically targeting the management of moderate-to-severe postoperative pain that lasts longer than 24 hours. By using this innovative approach, the research aims to reduce the risks associated with opioid use, such as addiction and adverse events, while improving the overall recovery experience for patients. The methodology involves ensuring that the gel can deliver effective drug concentrations directly to the surgical site, enhancing pain management outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients undergoing surgical procedures who are expected to experience moderate-to-severe postoperative pain lasting more than three days.
Not a fit: Patients who do not undergo surgical procedures or those with mild pain that does not require extended pain management may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly reduce the reliance on opioids for postoperative pain management, leading to safer recovery experiences for patients.
How similar studies have performed: Other research has shown promise in using extended-release formulations for pain management, but this specific approach with injectable gel technology is relatively novel.
Where this research is happening
Tempe, United States
- Sonoran Biosciences, INC. — Tempe, United States (Active)
Researchers
- Principal investigator: Overstreet, Derek James — Sonoran Biosciences, INC.
- Study coordinator: Overstreet, Derek James
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.